|
|
 |
|
Viewing report
|
|
|
|
North American Brain Tumor Consortium - Developmental Therapeutics Review - Q1 2011
Global Markets Direct, March 2011, Pages: 48
North American Brain Tumor Consortium – Developmental Therapeutics Review – Q1 2011
Summary
Global Market Direct’s pharmaceuticals report, “North American Brain Tumor Consortium – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by North American Brain Tumor Consortium.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of North American Brain Tumor Consortium with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of North American Brain Tumor Consortium’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in North American Brain Tumor Consortium’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate North American Brain Tumor Consortium’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of North American Brain Tumor Consortium in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with North American Brain Tumor Consortium.
- Avoid Intellectual Property Rights related issues.
|
|
|
|
